Skip to main content

Agendia, Agilent to Develop Dx Tests, Extend Supply Pact

NEW YORK (GenomeWeb News) – Agendia and Agilent Technologies announced today that they have extended a supply agreement and intend to collaborate on the development of new in vitro diagnostic tests.
 
According to a joint statement, the firms will collaborate on developing cancer diagnostic tests that will be run on Agilent microarrays.
 
In February 2007, Amsterdam, Netherlands-based Agendia received US Food and Drug Administration clearance for its MammaPrint diagnostic for breast cancer recurrence. The test, which is performed on an Agilent microarray, was the first in vitro diagnostic multivariate index assay device approved by the FDA since the agency released a draft guidance in 2006 describing such products.
 
The partners also announced that Agendia’s products will continue to be supplied on Agilent microarrays through Dec. 31, 2011. Agilent has been manufacturing the components for the Agendia assay since 2003, the firms said.
 
"We eagerly anticipate expanding our role beyond the manufacturing of Agendia products on the Agilent microarrays to helping them build validated diagnostic cancer tests, as well as developing and expanding the company's worldwide distribution channels,” Yvonne Linney, vice president and general manager of genomics for Santa Clara, Calif.-based Agilent, said in the statement.
 
Financial terms of the agreements were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.